ImageneBio Appoints Matt Robbins as General Counsel
ImageneBio, a Nasdaq-listed clinical-stage biotechnology company, announced the appointment of Matt Robbins as General Counsel effective July 7, 2026. Robbins brings over 15 years of legal experience in life sciences, including corporate governance, securities, and transactional expertise, to support ImageneBio's ongoing Phase 2 clinical programs f…